Advertisement

Medical Castration with LHRH Agonists and the Need for Combined Treatment with an Antiandrogen in Prostate Cancer

  • F. Labrie
  • A. Dupont
  • A. Bélanger
  • R. St-Arnaud
  • C. Labrie
  • C. Bossé
  • R. Delisle
  • J. Emond
  • J. G. Girard
  • J. G. Houle
  • Y. Lacoursière
  • G. Monfette
  • J. P. Paquet
  • A. Vallières
Part of the Biochemical Endocrinology book series (BIOEND)

Abstract

Cancer of the prostate is the second cause of death due to cancer in man, its annual incidence being approximately 40,000 new cases per 100 millions of population in North America. A major change in the treatment of this disease has been introduced by the pioneering studies of Huggins and collaborators who have recognized the role of androgens of testicular origin in the evolution of this cancer (Huggins and Hodges, 1941; Huggins et al., 1941). Following these observations, during the last forty years, neutralization of testicular androgens has been achieved by surgical castration or treatment with estrogens, two approaches which lead to subjective and/or objective improvement in 60 to 70% of cases for various time intervals (Bailar et al., 1970; Barnes and Ninan, 1972; Byar, 1973; Grayhack and Kozlowski, 1980; Murphy and Slack, 1980; Nesbit and Plumb, 1946; Nesbit and Baum, 1950; Staubiz et al., 1954; Whitmore, 1956). However, surgical castration presents psychological limitations for many patients while high doses of estrogens frequently cause lethal cardiovascular complications (Byar, 1973). There was thus the need for a more acceptable way of neutralizing testicular androgens.

Keywords

Prostatic Cancer Advanced Prostatic Cancer Adrenal Androgen LHRH Agonist Surgical Castration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Acevedo, H.F., and Goldziecker, J.W., 1965, Further studies on the metabolism of 4-[4–14C]androstene3,17-dione by normal and pathological human prostate tissue. Biochim. Biophys. Acta., 97: 564.PubMedCrossRefGoogle Scholar
  2. Auclair, C., Kelly, P.A., Coy, D.H., Schally, A.V., and Labrie, F., 1977a, Potent inhibitory activity of [D-Leu6, des-Gly-NH2 10]LHRH ethylamide on LH/hCG and PRL testicular receptor levels in the rat. Endocrinology, 101: 1890.CrossRefGoogle Scholar
  3. Auclair, C., Kelly, P.A., Labrie, F., Coy, D.H. and Schally, A.V., 1977b, Inhibition of testicular luteinizing hormone receptor levels by treatment with a potent luteinizing hormone-releasing hormone agonist or human chorionic gonadotropin. Biochem. Biophys. Res. Commun., 76: 855.CrossRefGoogle Scholar
  4. Ballar, J.C., Byar, D.P., and Vet. Adm. Coop. Urol. Res. Group, 1970, Estrogen treatment for cancer of the prostate. Cancer, 26: 257.CrossRefGoogle Scholar
  5. Barnes, R.W., and Ninan, C.A., 1972, Carcinoma of the prostate: biopsy and conservative therapy. J. Urol., 108: 897.PubMedGoogle Scholar
  6. Bélanger, A., Labrie, F., Lemay, A., Caron, S. and Raynaud, J.P., 1980, Inhibitory effects of a single intranasal administration of [D-Ser(TBU)6, des-Gly- NH210]LHRH ethylamide, a potent LHRH agonist, on serum steroid levels in normal adult men. J. Steroid Biochem., 13: 123.PubMedCrossRefGoogle Scholar
  7. Bhanalaph, T., Varkarakis, M.J., and Murphy, G.P., 1974, Current status of bilateral adrenalectomy of advanced prostatic carcinoma. Ann. Surg. 179: 17.PubMedCrossRefGoogle Scholar
  8. Blackard, C.E. and The Veteran’s Administration Cooperative Urology Research Group, 1975a, Studies of carcinoma of the prostate: a review. Cancer Chemother. Rep., 59: 225.Google Scholar
  9. Blackard, C.E., Byar, D.P., Seal, U.S., Doe, R.P. and VACURG, 1975b, Correlation of pretreatment serum nonprotein-bound cortisol and total 17-hydroxycorticosteroid values with survival in patients with prostatic cancer. New Engl. J. Med., 291: 751.CrossRefGoogle Scholar
  10. Blaquier, J., Forchielli, E. and Dorfman, R.I., 1967, In vitro metabolism of androgens in whole human blood. Acta Endocrinol., 55: 697.PubMedGoogle Scholar
  11. Byar, D.P., 1973, The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate. Cancer, 32: 1126.PubMedCrossRefGoogle Scholar
  12. Cowley, T.H., Brownsey, B.G., Harper, M.E., Peeling, W.B., and Griffiths, K., 1976, The effect of ACTH on plasma testosterone and androstenedione concentrations in patients with prostatic carcinoma. Acta Endocrinol., 81: 310.PubMedGoogle Scholar
  13. De Grouchy, J., 1973, Cancer and the evolution of species: a ransom. Biomedicine, 18: 6.PubMedGoogle Scholar
  14. Faure, N., Labrie, F., Lemay, A., Bélanger, A., Gourdeau, Y., Laroche, B., and Robert, G., 1982, Inhibition of serum androgen levels by chronic intranasal administration of a potent LHRH agonist in adult men. Fertil. Steril., 37: 416.PubMedGoogle Scholar
  15. Fowler, J.E. Jr., and Whitmore, W.F. Jr., 1980, The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J. Urol., 126: 372.Google Scholar
  16. Gallegos, A.J., and Berliner, D.L., 1967, Transformation and conjugation of dehydroepiandrosterone by human skin. J. Clin. Endocrinol. Metab., 27: 1214.PubMedCrossRefGoogle Scholar
  17. Geller, J., Albert, J., Loza, D., Geller, S., Stoeltzing, W., and De La Vega, D., 1978, DHT concentrations in human prostate cancer tissue. J. Clin. Endocrinol. Metab., 46: 440.PubMedCrossRefGoogle Scholar
  18. Glode, L.M. (Abbott Prostatic Cancer Study), 1982, Leuprolide therapy of advanced prostatic cancer.. LASCO Proc., Abst., p. 110.Google Scholar
  19. Grayhack, J.T. and Kozlowski, J.M., 1980, Endocrine therapy in the management of advanced prostatic cancer: the case for early initiation of treatment. Urol. Clin. North Amer., 7: 639.Google Scholar
  20. Harper, M.E., Peeling, W.B., Cowley, T., Bronsey, B.G., Phillips, M.E.Z., Groom, G., Fahmy, D.R., and Griffiths, K., 1974, Plasma steroid and protein hormone concentration in patients with prostatic carcinoma before and during estrogen therapy. Acta Endocrinol., 81: 409.Google Scholar
  21. Harrisson, J.H., Thorn, G.W., and Jenkins, D., 1953, Total adrenalectomy for reactivated carcinoma of the prostate. N. Engl. J. Med., 248: 86.CrossRefGoogle Scholar
  22. Huggins, C., and Hodges, C.V., 1941, Studies of prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1: 293.Google Scholar
  23. Huggins, C., Stevens, R.E., and Hodges, C.W., 1941, Studies on prostatic cancer. II. The effects of castration of advanced carcinoma of the prostate gland. Arch. Surg., 43: 209.CrossRefGoogle Scholar
  24. Huggins, C., and Scott, W.W., 1945, Bilateral adrenalectomy in prostatic cancer. Ann. Surg., 122: 1031.CrossRefGoogle Scholar
  25. Johnson, D.E., Kaesler, K.E., and Ayala, A.G., 1975, Megestrol acetate for treatment of advanced carcinoma of the prostate. J. Surg. Oncol. 7: 9.PubMedCrossRefGoogle Scholar
  26. Knapstein, P., David, A., Wu, C.H., Archer, D.F., Flickinger, G.L., and Touchstone, J.C., 1968, Metabolism of free and sulfoconjugated DHEA in brain tissue in vivo and in vitro. Steroids 11: 885.PubMedCrossRefGoogle Scholar
  27. Krabbe, S. and Shakkeback, N.E., 1977, Gonadotropinreleasing hormone (LHRH) and human chorionic gonadotropin in the treatment of two boys with hypogonadotrophic hypogonadism. Acta Paediatr. Scand., 66: 361.PubMedCrossRefGoogle Scholar
  28. Labrie, F., Auclair, C., Cusan, L., Kelly, P.A., Pelletier, G. and Ferland, L., 1978, Inhibitory effects of LHRH and its agonists on testicular gonadotropin receptors and spermatogenesis in the rat. In Hansson, V. (ed.), Endocrine Approach to Male Contraception, Int. J. Androl. ( Suppl. 2 ), pp. 303.Google Scholar
  29. Labrie, F., Bélanger, A., Cusan, L., Séguin, C., Pelletier, G., Kelly, P.A., Lefebvre, F.A., Lemay, A., and Raynaud, J.P., 1980, Antifertility effects of LHRH agonists in the male. J. Androl., 1: 209.Google Scholar
  30. Labrie, F., Dupont, A., Bélanger, A., Cusan, L., Lacourcière, Y., Monfette, G., Laberge, J.G., Emond, J.P., Fazekas, A.T.A., Raynaud, J.P. and Husson, J.M., 1982, New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. J. Clin. Invest. Med., 5: 267.Google Scholar
  31. Labrie, F., Dupont, A., Bélanger, A., Lacourcière, Y., Raynaud, J.P., Husson, J.M., Gareau, J., Fazekas, A.T.A., Sandow, J., Monfette, G., Girard, J.G., Emond, J. and Houle, J.G., 1983a, New approach in the treatment of prostate cancer: complete instead of only partial withdrawal of androgens. The Prostate, 4: 579.PubMedCrossRefGoogle Scholar
  32. Labrie, F., Dupont, A., Bélanger, A., Lefebvre, F.A., Cusan, L., Raynaud, J.P., Husson, J.M. and Fazekas, A.T.A., 1983b, New Hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist. Hormone Res., 18: 18.PubMedCrossRefGoogle Scholar
  33. Labrie, F., Dupont, A., Bélanger, A., Lefebvre, F.A., Cusan, L., Monfette, G., Laberge, J.G., Emond, J.P., Raynaud, J.P., Husson, J.M. and Fazekas, A.T.A., 1983c, New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen. J Steroid Biochem., 19: 999.PubMedCrossRefGoogle Scholar
  34. Labrie, F., Bélanger, A., Carmichael, R., Séguin, C., Lefebvre, F.A., Faure, N., and Dupont, A., 1983d, Inhibition of the testicular steroidogenic pathway in experimental animals and men, in: “Recent Advances in Male Reproduction: Molecular Basis and Clinical Implications”, R. D’Agata, M.B. Lipsett and H.J. Van der Molen (eds), Raven Press, New York, p. 239.Google Scholar
  35. Labrie, F., Dupont, A., Bélanger, A., Labrie, C., Lacourcière, Y., Raynaud, J.P., Husson, J.M., Emond, J., Houle, J.G., Girard, J.G., Monfette, G., Paquet, J.P., Vallières, A., Bossé, C., and Delisle, R., 1984a, Combined antihormonal treatment in prostate cancer, a new approach using an LHRH agonist or castration and an antiandrogen, in: Hormones and Cancer, Raven Press, New York, in press.Google Scholar
  36. Labrie, F., Dupont, A., Bélanger, A., Emond, J., and Monfette, G., 1984b, Pure antiandrogens permit to take advantage of the well-tolerated LHRH agonists for the treatment of prostate cancer. Proc. Natl. Acad. Sci. USA, in press.Google Scholar
  37. Lefebvre, F.A., Séguin, C., Bélanger, A., Caron, S., Sairam, M.R., Raynaud, J.P., and Labrie, F., 1982, Combined long-term treatment with an LHRH agonist and a pure antiandrogen blocks androgenic influence in the rat. The Prostate, 3: 569.PubMedCrossRefGoogle Scholar
  38. MacFarlane, D.A., Thomas, L.P., and Harrison, J.H., 1960, A survey of total adrenalectomy in cancer of the prostate. Amer. J. Surg. 99: 562.PubMedCrossRefGoogle Scholar
  39. Markland, F.S., Chiopp, R.T., Cosgrove, M.D., and Howard, E.B., 1978, Characterization of steroid hormone receptors in the Dunning R-3327 rat prostatic adenocarcinoma. Cancer Res., 38: 2818.PubMedGoogle Scholar
  40. Menon, M. and Walsh, P.C., 1979, Hormone therapy for prostatic cancer. in: “Prostatic Cancer”, G.P. Murphy, ed., Littleton, Massachusetts, PSG Publishing Co., p. 175.Google Scholar
  41. Morales, P.A., Brendler, H., and Hotchkiss, R.S., 1955, The role of the adrenal cortex in prostatic cancer. J. Urol., 73: 399.PubMedGoogle Scholar
  42. Murphy, G.P. and Slack, N.H., 1980, Response criteria for the prostate of the USA National Prostatic Cancer Project. Urol. Clin. North Amer., 7: 631.Google Scholar
  43. Nesbit, R.M. and Plumb, R.T., 1946, A follow-up on 795 patients treated prior to the endocrine era and a comparison of survival rates between these and patients treated by endocrine therapy. Surgery, 20: 263.PubMedGoogle Scholar
  44. Nesbit, R.M. and Baum, W.C., 1950, Endocrine control of prostatic carcinoma. Clinical and statistical survey of 1818 cases. J. Amer. Med. Assoc. 143: 1317.CrossRefGoogle Scholar
  45. Pike, A., Peeling, W.B., Haerper, M.E., Pierrepoint, C.G., and Griffiths, K., 1970, Testosterone metabolism in vivo by human prostatic tissue. Biochem. J., 120: 443.PubMedGoogle Scholar
  46. Resko, J., Bélanger, A., and Labrie, F., 1982, Effects of chronic treatment with a potent LHRH agonist on serum LH and steroid levels in the male rhesus monkey. Biol. Reprod., 26: 378.PubMedCrossRefGoogle Scholar
  47. Resnick, M.I., and Grayhack, J.T., 1975, Treatment of stage IV carcinoma of the prostate. Urol. Clin. North Amer., 2: 141.Google Scholar
  48. Sandow, J. and Hahn, M., 1978, Chronic treatment with LHRH in golder hamsters. Acta Endocrinol. 88: 601.PubMedGoogle Scholar
  49. Sanford, E.J., Paulson, D.F., Rohner, T.J., Drago, J.R., Santen, R.J. and Bardin, C.W., 1977, The effects of castration on adrenal testosterone secretion in men with prostatic carcinoma. J. Urol., 118: 1019.PubMedGoogle Scholar
  50. Santen, R.J., Warner, B., Demers, L.M., Dufau, M., and Smith, J., 1984, Use of GnRH hormone agonists analogues. in: “ LHRH and its analogs -a new class of contraceptive and therapeutic agents”, B. Vickery, J.J. Nestor, Jr. and E.S.E. Hafez (eds), MTP Press, Lancaster-Boston, in press.Google Scholar
  51. Schubert, G.E., 1975, Hormone dependency and histological types of tumors, in: “Hormone Therapy of Prostate Cancer”, U. Bracci and F. Di Silverio, (eds), Cofese Edizione, Rome, Palermo, p. 43.Google Scholar
  52. Schwartzstein, L., 1976, Diagnostic and therapeutic use of LHRH in the infertile man, in: “Hypothalamus and endocrine functions”, F. Labrie, J. Meites and G. Pelletier, eds, Plenum Press, New York, p. 73.Google Scholar
  53. Scott, W.W., 1983, Historical overview of the treatment of prostatic cancer. The Prostate 4: 435.PubMedCrossRefGoogle Scholar
  54. Séguin, C., Cusan, L., Bélanger, A., Kelly, P.A., Labrie, F., and Raynaud, J.P., 1981, Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on adrogen-dependent tissues in the rat. Mol. Cell. Endocrinol., 21: 37.PubMedCrossRefGoogle Scholar
  55. Sogani, P.C., Ray, B., and Whitmore, W.F. Jr., 1975, Advanced prostatic carcinoma: flutamide therapy after conventional endocrine treatment. Urology, 6: 164.PubMedCrossRefGoogle Scholar
  56. Sommerville, I.F., Flamigni, C., Collins, W.P., Koullapis, E.N., and Dewhurst, C.J., 1971, Androgen metabolism in human skin. Proc. Roy Soc. Med., 64: 845.PubMedGoogle Scholar
  57. Staubiz, W.J., Oberlkircher, O.J. and Lent, M.H., 1954, Clinical results of the treatment of prostatic carcinoma over a ten-year period. J. Urol., 72: 939.Google Scholar
  58. Stoliar, B., and Albert, D.J., 1974, SCH 13521 in the treatment of advanced carcinoma of the prostate. J. Urol., 111: 803.PubMedGoogle Scholar
  59. Tolis, G., Ackman, D., Stellos, A., Mehta, A., Labrie, F., Fazekas, A.T.A., Comaru-Schally, A.M. and Schally, A.V., 1982, Tumor growth inhibition in patients with prostatic carcinoma treated with agonists of LHRH. Proc. Natl. Acad. Sci. USA 79: 1658PubMedCrossRefGoogle Scholar
  60. Trachtenberg, J., 1983, The treatment of metastatic prostatic cancer with a potent luteinizing hormone-releasing hormone analogue. J. Urol., 129: 1149.PubMedGoogle Scholar
  61. Van der Molen, H.J., and Groen, D., 1968, Interconversion of progesterone and 20a-dihydroprogesterone and of androstenedione and testosterone in vitro by blood and erythrocytes. Acta Endocrinol., 58: 419.PubMedGoogle Scholar
  62. Whitmore, W.F. Jr., 1956, Hormone therapy in prostatic cancer. Amer. J. Med., 21: 697.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • F. Labrie
    • 1
  • A. Dupont
    • 1
  • A. Bélanger
    • 1
  • R. St-Arnaud
    • 1
  • C. Labrie
    • 1
  • C. Bossé
    • 1
  • R. Delisle
    • 1
  • J. Emond
    • 1
  • J. G. Girard
    • 1
  • J. G. Houle
    • 1
  • Y. Lacoursière
    • 1
  • G. Monfette
    • 1
  • J. P. Paquet
    • 1
  • A. Vallières
    • 1
  1. 1.Departments of Medicine and Molecular EndocrinologyCHULQuébecCanada

Personalised recommendations